Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study - Concepedia

Concepedia

Publication | Open Access

Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study

DOI Full Paper Access

35

Citations

26

References

2023

Year

Julia Brandts, Sarah Bray, Guillermo Villa, Alberico L. Catapano, Neil R Poulter, Antonio J. Vallejo‐Vaz, Kausik K. Ray

The Lancet Regional Health - Europe

Abstract

Amgen.

References

	Year	Citations
2018 ESC/ESH Guidelines for the management of arterial hypertension Bryan Williams, Giuseppe Mancia, Wilko Spiering, European Heart Journal	2018	10.1K
2019 ESC/EAS Guidelines for the management of dyslipidaemias: <i>lipid modification to reduce cardiovascular risk</i> François Mach, Colin Baigent, Alberico L. Catapano, European Heart Journal	2019	8.4K
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia Frederick J. Raal, David Kallend, Kausik K. Ray, New England Journal of Medicine	2020	755
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial Frederick J. Raal, Evan A. Stein, Robert Dufour, The Lancet Metabolic SyndromeLipid DisorderHeterozygous Familial HypercholesterolaemiaOxysterolMedicine	2014	734
EU-Wi<i>d</i>e Cross-Section<i>a</i>l Obser<i>v</i>at<i>i</i>o<i>n</i>al Study of Lipid-Modifying Therapy Use in Se<i>c</i>ondary and Pr<i>i</i>mary Care: the DA VINCI study Kausik K. Ray, Bart Molemans, W. Marieke Schoonen, European Journal of Preventive Cardiology	2020	699
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia John J.P. Kastelein, Henry N. Ginsberg, Gisle Langslet, European Heart Journal	2015	530
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease Michelle L. O’Donoghue, Robert P. Giugliano, Stephen D. Wiviott, Circulation	2022	349
Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study Heart	2002	295
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study Kausik K. Ray, Inaam Haq, Aikaterini Bilitou, The Lancet Regional Health - Europe	2023	273
An International Model to Predict Recurrent Cardiovascular Disease Peter W.F. Wilson, Ralph B. D’Agostino, Deepak L. Bhatt, The American Journal of Medicine Heart FailureCardiovascular DiseaseAtherosclerosisInternational ModelPublic Health	2012	239

Page 1